Wednesday, 8 July 2020

Medical Drones Market Expected To Grow At High Cagr During Forecast Period 2019 – 2025

Market Forecast
Medical Drones’ Market is expected to worth USD 398 Million by 2025 and is anticipated to register a CAGR of 24.4% during the forecast period (2019 to2025).
Market Synopsis
Medical drones help in the transport of medical supplies such as vaccines, medications, and medical aids. These drones are deployed in remote or inaccessible areas for the rapid & secure distribution of medical supplies and the war-torn regions from medical facilities. Rising public acceptance of medical drone is also driving the growth in medical drones industry demand.
Medical Drones Market Size, In recent years, has been seeking the attention of healthcare providers and governments to offer better healthcare services to remote locations. These drones help in on-time delivery of vaccines, medication, blood, and supplies to the origin and thereby reduce the outbreaks of life-threatening infectious diseases.
How can this technology help in improving safety and care delivery?
  • Bedside medication delivery
  • Effective treatment from the distance
  • Easy reach to an isolated place
  • Pre-treatment facility till the time emergency service arrives at takeover
Most of the key players in the market are focusing on developing medical drones to deliver medical supplies to far distances. For instance, in 2016, a Nevada based start-up Flirtey delivered medical test materials and supplies to and from an offshore vessel. This was the first successful ship to shore delivery in the U.S.
Market Influencer
Increasing investments by key players in R&D is the key factor driving the growth of the Global Medical Drones’ Market.
Market Drivers
  • Rising participation of Governments in various countries: Active involvement of local governments towards the deployment of drone service to remote and isolated areas is boosting the growth of the market. For instance, in 2018, the government of Ghana has signed an agreement with Zipline (US) for the deployment of drones throughout the country to provide medical supplies to untapped regions
  • Increasing application of drone for the supply of medical products such as blood, pharmaceuticals/drugs, and vaccines are anticipated to propel the market growth during the forecast period
  • Technological advancements to improving the accuracy of medical drones during emergency cases backed by R&D activities by key players
Market Restraints
  • Medical drones. Medical drones are not allowed to fly without the permission of the government. Thus, product approval laws are expected to restrict the growth of the medical drone’s market during the forecast period.
Segmentation
By Application
  • Blood Transfer: Rising incidence of severe bleeding deaths is boosting the demand for medical drones. The blood transfer segment is anticipated to show a growth rate of ~24% during the analysis period. According to the MRFR analysis, each year, around 60,000 Americans die from blood loss or hemorrhaging. Moreover, around 2 million people die across the globe.
  • Pharmaceutical/Drugs Transfer: The increasing focus of key medical drones vendors towards the development of drones for medication delivery is boosting the growth of this segment.
  • Vaccines Transfer: This segment is mainly on the drones that are associated with the delivery of the vaccine.
By End-User
  • Emergency Medical Services: This segment held the largest market share in 2018, owing to continues advancements in technology. For instance, in 2019, an automated drone’s delivery company Zipline (US), has planned for the expansion of a medical drone network into Ghana for emergency services.
  • Blood Banks: Owing to poor road conditions, transporting blood in underdeveloped countries is a huge task. Medical drones carry blood, plasma, and platelets from blood banks to remote hospitals and clinics.
By Region
  • Americas: The Americas held the largest regional market in 2018, owing to rising technology advancement. Moreover, the governments in this region are also promoting the acceptance of medical drones, as a result, players are aggressively working to develop advanced drones. In October 2019, United Parcel Services (US) received an authority from the Federal Aviation Administration to deliver medical packages at hospitals across the country.
  • Europe: The European market is expected to be the second-largest market in 2025. The market growth in this region can be attributed to government funding and support to the healthcare sector, coupled with increasing research and development.
  • Asia-Pacific: Asia-Pacific is the fastest-growing region for the medical drones market owing to the improving healthcare infrastructure, rising investments in healthcare, and expansions by market players in the region. Also, countries such as India and China are expected to be the fastest-growing in the region due to the focus of governments towards the adoption of new technologies and faster adoption of best treatment options from developed countries.
  • Middle East & Africa: It is projected to account for the least share of the global market due to an underdeveloped healthcare sector.
Key Players
  • DJI (China)
  • DHL (Germany)
  • Embention (Spain)
  • Flirtey (US)
  • Matternet (US)
  • Vayu (US)
  • Zipline (US)
  • EHang (China)
  • TUDelft (Netherlands)
Posted by at No comments:

Digital 3D Printing Market Research Report 2019 Analysis And Forecast To 2025

Digital 3D Printing Market size is expected to register a CAGR of 20.54% to reach USD 5,214.8 Million by 2025. 3D Printing is a process in which physical objects are created by depositing materials in layers based on a digital model. The creation of a 3D printed object is achieved using additive processes. In an additive process, an object is created by laying down successive layers of materials until the object is created. 3D Printing enables to produce complex shapes using less material than traditional manufacturing methods. Each 3D Printing process requires software, hardware, and materials to work together.
Market Dynamics
Increasing applications of Digital 3D Printing in healthcare industry is expected to boost market growth. 3D Printing techniques have empowered medical practitioners, manufacturers of medical devices, as well as researchers due to their use in dental & orthodontic treatments, orthopedic implants, tissue engineering, and drug development. As a result, the increasing benefits of the mentioned applications would boost digital 3d printing market growth. 3D Printing technique is useful to speed up procedures and helps to minimize the trauma faced by patients due to conventional treatment options. Technological advancements in digital 3D Printing, rising public-private funding for 3D Printing activities are the major drivers that contribute to the growth of the digital 3D Printing market.
Segmentation
Global Digital 3D Printing Market analysis is segmented based on Component, Material, Technology, Application and End User.
The market, based on component, has been categorized as system/device and software/services. System/Device held 867.53 market value in 2018
Global digital 3D Printing market, based on material, has been segregated into polymers, metal & alloy, ceramics, and others.
Global digital 3D Printing market trends based on technology, has been segregated into stereolithography, deposition modeling, laser sintering, jetting technology, electron beam melting, and others.
Global digital 3D Printing market based on application has been categorized into dental, prosthetics, orthopedics, medical components, tissue engineering, hearing aids, drug screening, and others.
Global digital 3D Printing market, based on end user, has been segregated into hospitals & surgical centers, dental clinics & laboratories (offices), pharmaceutical & biotechnology companies, and others.
Regional Analysis
Global Digital 3D Printing Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas led the market and accounted for the largest share in 2018, owing to the existence of medical device companies and the rising prevalence of diseases along with increased adoption of treatment by patients. In North America, the US held the largest of the market share in 2018 owing to the presence of major market players, developed healthcare infrastructure, high awareness, and availability of advanced treatment options. For instance, in November 2015, a group of medical researchers from North Carolina’s Wake Forest University developed a method to print the 3D form of custom medications in the configuration of pills. As a result, increasing applications of 3D Printing is expected to drive the market growth.
Europe accounts for the second-largest share in the global digital 3D Printing market owing to the presence of favorable government initiatives & laws and target population base, rising prevalence of lifestyle-associated conditions, and the presence of developed economies such as Germany, the UK, and France. Since the ban on animal testing for cosmetics in 2013, the wellness industry had been a significant supporter of 3D Printing in Europe.
Asia-Pacific is estimated to be the fastest-growing market during the forecast period due to the increasing per capita health spending, growing older population base, rising incidence of accidents, and developing the healthcare sector in China, Japan, India, and Australia.
The Middle East & Africa digital 3D Printing market is segmented into two major regions, namely the Middle East and Africa. In this region, the Middle East is anticipated to dominate owing to the presence of countries such as Egypt, Saudi Arabia, and others. The Middle East and Africa has less economic developments and extremely low-income due to which the region accounts for the least market share but is expected to grow with the increasing cases of chronic diseases and demand for better treatments in countries.
Key Players
The Prominent Players in the Global Digital 3D Printing Market are Stratasys Ltd (US), 3D Systems, Inc. (US), Carbon, Inc. (US), EnvisionTEC (US), Formlabs (US), ExOne (US), Materialise (Europe), General Electric (US), Micron Dental (US), Renishaw PLC (UK).
Some of the key strategies followed by players operating in the Global Digital 3D Printing Market were acquisitions, expansions, product launches, partnerships, mergers, collaborations, alliances, and product approvals.
  • In June 2019, Materialise received the FDA clearance for the cardiovascular planning software suite. Thus, the suite has helped clinicians to produce patient-specific 3D models for more than 20 years.
  • In November 2019, ExOne introduced the X1 160PRO metal 3D printer for high-volume production of quality parts.
  • In February 2019, EnvisionTEC and AvaDent digital dental solutions announced a new partnership. This partnership offered a complete digital workflow solution for digital dentures, from impressions and digital design to try-in and final restoration.
Posted by at No comments:

Current And Forthcoming Hyperspectral Imaging System Market Size In Terms Of Volume And Value 2019

Global Hyperspectral Imaging System Market held a value of USD 10,700 Million in 2018, at a CAGR of 17.4% during the assessment period of 2019 to 2025.
Hyperspectral Imaging System Market Synopsis
Hyperspectral Imaging Systems (HIS) are also known as imaging spectroscopy. It was originated from remote sensing and has various applications in surveillance, remote sensing, machine vision/optical, and medical diagnostics. It can acquire 2D images across a wide range of the electromagnetic spectrum. Increasing applications for research in life sciences and the medical diagnostics sector in the past few years are responsible for a surge in demand for hyperspectral imaging systems. The key players involved in this market are actively focusing upon building partnerships, collaborations, and joint ventures with hospitals and ambulatory centers to strengthen their position in the market. Moreover, there is an increasing growth in various chronic diseases, which pushes the need for efficient hyperspectral imaging systems in the developing as well as underdeveloped regions.
Hyperspectral Imaging System Market Influencer
Rising funding and investments for the development of hyperspectral medical imaging systems are likely to provide favorable conditions for the growth of the hyperspectral medical imaging system market during the forecast period.
Hyperspectral Imaging System Market Drivers
  • The growing industrial applications of hyperspectral imaging is anticipated to drive the growth of the market during the forecast period. It has various applications in food & agriculture, healthcare, defense, mining, and metrology industries.
  • Innovative and easy to use product launched in recent years
  • Rising spending on scientific research and aerospace industry
  • The growing prevalence of cancer and increasing awareness of innovative diagnostics methods is providing favorable conditions for the growth of the market during the forecast period. According to the US Department of Health and Human Services, 1,735,350 new cases of cancer were detected in the US in 2018. It is expected to accelerate the demand for hyperspectral imaging systems during the study period
  • High investment in research and development for the development of efficient imaging solutions
Market Restraints
  • High costs associated with HIS are likely to hamper the market growth
  • Data storage-related issues associated with HIS
Hyperspectral Imaging System Market Segmentation
By Product
  • Visible/Near-Infrared (VNIR): These systems create a false-color composite image made using near-infrared, green, and blue wavelengths. They are used in healthcare and agriculture sectors. VNIR segment is estimated to hold the largest market share during the forecast period due to the ease in operating and high efficiency of VNIR products
  • Mid-Wave Infrared (MWIR): Mid-Wave Infrared (MWIR) systems operate in wavelengths ranging from 3µm to 5µm (3000nm to 5000nm). This segment is anticipated to be the fastest-growing segment owing to the rising adoption of MWIR systems in detecting volcanic vents, industrial gas leaks, or biomass burning events.
  • Short-Wave Infrared (SWIR): It operates in wavelengths between 1,050 and 2,500 nm and used in inspection, sorting, and quality control. It has various applications including surveillance and remote sensing.
  • Long-Wave Infrared (LWIR): Long-Wave Infrared (LWIR) systems are used in the detection of minerals such as quartz, adularia, albite, kaolinite, orthoclase, Na- and Ca-montmorillonite, calcite, opal, chalcedony, gypsum, alunite, jarosite, and other sulfates.
By Technology
  • Pushbroom: These devices are made up of digital micromirror devices (DMD), CMOS image sensors. It is also called a line scan. This segment is estimated to hold maximum market share during the forecast period. The growth of this segment is attributed to the growing popularity of push broom systems in computer vision, remote sensing, biomedicine, surveillance, precision agriculture, environmental studies, forensics, nanoparticle research, food science, mining, forestry, etc.
  • Snapshot: Snapshot hyperspectral imagers are fast as compare to other systems. This segment is expected to register the fastest CAGR during the forecast period.
  • Others: Others include whiskbroom, tunable filter, and other technologies.
By Application
  • Surveillance: The majority of the hyperspectral imaging systems are used for defense and surveillance. Additionally, it can detect satellites, high-altitude reconnaissance aircraft, medium-altitude commercial aircraft, and drones. The market growth of the segment is majorly attributed to the increasing adoption of innovative technologies in the defense sector, along with the rising applications of unmanned aerial vehicles for surveillance purposes.
  • Medical Diagnostics: Medical diagnostics segment is anticipated to be the fastest-growing segment owing to the increasing applications of the hyperspectral imaging system in healthcare, such as the detection of the chemical composition of human tissues. Additionally, it has potential applications in non-invasive diagnosis.
  • Remote Sensing: Remote sensing is likely to hold significant market share in the global hyperspectral imaging system market. It is also known as imaging spectroscopy. It is used for the detection and identification of minerals, terrestrial vegetation, and human-made materials and backgrounds.
  • Machine Vision/Optical: Various hyperspectral imaging systems are used for machine vision/optical purposes.
By Region
  • Americas: Americas is estimated to be the largest regional market owing to the presence of prominent players in the major countries in America. Major market players such as Headwall Photonics, Inc., Resonon, Inc., Corning Incorporated, Applied Spectral Imaging, and Surface Optics Corporation have a significant presence in the Americas. The region is anticipated to dominate the global hyperspectral imaging system market owing to the well-established healthcare sector and rising healthcare spending in the region. According to the Committee for a Responsible Federal Budget, in 2017, the US has spent more than USD 3.5 trillion on healthcare-related expenses.
  • Europe: The European region holds the second largest share as there is increasing support from regulatory authorities to control cancer. Moreover, the rising expenses on defense and surge in demand for innovative and easy to use hyperspectral imaging systems have led to an increase in demand for hyperspectral imaging systems in the region.
  • Asia-Pacific: The Asia-Pacific region is anticipated to be the fastest-growing region in the global hyperspectral imaging system market. This region is witnessing a surge due to the increasing mining activities, and growing biotechnology and agriculture sector in developing countries such as India. According to the India Brand Equity Foundation, the Indian biotechnology sector is likely to reach around USD 12 billion in the year 2018. The growing biotechnology sector is likely to provide favorable conditions and anticipated to drive growth in the market.
  • Middle East & Africa: The smallest market due to limited healthcare infrastructure and limited exposure to innovative solutions.
Key Players
  • Headwall Photonics, Inc.
  • Specim, Spectral Imaging Ltd.
  • Norsk Elektro Optikk as (NEO)
  • Resonon, Inc.
  • Corning Incorporated
  • Telops
  • Applied Spectral Imaging
  • Bayspec, Inc.
  • Surface Optics Corporation
  • Chemimage Corporation
  • Cubert GmbH
  • Raytheon
  • Galileo Group, Inc.
  • Hypermed Imaging, Inc.
  • Inno-Spec
  • Camlin Group Ltd.
  • IMEC
  • XIMEA GmbH
  • Others
Posted by at No comments:

Latest Study Offers Detailed Insights On Thalassemia Treatment Market 2019

Market Forecast
Thalassemia Treatment Market Size is expected to cross USD 3763 Million by 2025 at a CAGR of 10.4%.
Thalassemia, specifically the Beta- thalassemia disorder, is majorly caused by the mutation in the Hemoglobin Subunit Beta (HBB) gene. For instance, at least 5.2% of the world population and over 7% of pregnant women have a genetic mutation.
Market Synopsis
Thalassemia Treatment Market analysis asserts that, Thalassemia is an inherited blood disorder wherein the body makes an inadequate amount of hemoglobin. Hemoglobin disorders were initially prevalent in 60% of 229 countries, that potentially affected 75% of births, but are now sufficiently common in 71% of countries amongst 89% of births.
Market Influencers
Major companies are concentrating on mergers and acquisitions, new product developments, approvals, and regional expansions. For instance, in September 2019, Bluebird Bio, Inc. (US) has approved the first gene therapy for Beta-thalassemia. This gene therapy eliminates the need for blood transfusions in patients with β-thalassemia. Thus, major manufacturers are focusing on approvals in thalassemia treatment, which ultimately drives the growth of the market.
Market Drivers
  • The rising incidence of thalassemia is expected to drive the growth of the market. Patients with insufficient hemoglobin suffer from thalassemia. For instance, thalassemia affects approximately 4.4 of every 10,000 live births throughout the world.
  • Increasing pipeline drugs in thalassemia is expected to drive the growth of the market. There are approximately 15 pipeline products under clinical trials for the treatment of thalassemia. For instance, in December 2016, Kiadis Pharma announced initiation of Phase I/II clinical trial with ATIR201 for thalassemia.
  • A rise in awareness regarding available treatment options for the treatment of thalassemia is expected to drive the growth of the market.
  • The rise in demand for improved curative gene therapy is expected to drive the growth of the market.
Market Restraints
  • Stringent regulatory policies
  • High treatment costs
Segmentation
By Type
  • Alpha-thalassemia: Fastest growing segment. It is one of the most common autosomal recessive disorders. There is an increased incidence of the alpha-globin disorders in the US and other Western nations which eventually drives the growth of the thalassemia treatment market. However, about 5% of the world’s population is affected by alpha-thalassemia.
  • Beta Thalassemia: It is caused by reduced or no production of beta-globin subunits. About 1.5% of the global population is affected by Beta-thalassemia.
By Treatment
  • Blood Transfusions: The largest growing segment owing to the low risks involved due to careful blood screening. This treatment gives strong red blood cells along with normal hemoglobin. About 56,000 population have major thalassemia, wherein, at least 30,000 need regular blood transfusions. Thus, rising demand for blood transfusions is expected to drive the growth of the market.
  • Iron Chelation Therapy: This includes removing excess iron from the bloodstream. Iron chelator drugs such as desferrioxamine, deferiprone, and deferasirox are majorly used in this treatment.
  • Folic Acid Supplements: Folic acid is vitamin B that helps build strong red blood cells. These supplements are majorly consumed during and after pregnancy. However, 4% had started consuming after becoming pregnant. Thus, the increased use of folic acid is expected to drive the growth of this segment.
  • Gene therapy: Scientists are investigating genetic techniques to treat thalassemia. Gene therapy named Zynteglo was first launched by Bluebird Bio, Inc. (US) in September 2019.
  • Bone Marrow transplants: These transplants are not done very often as significant risks are involved but can be tried if no bone marrow matched donor is available. However, the patient will not need further blood transfusions if this transplantation is done. As a result, it would drive the market growth in this segment.
By End-User
  • Hospitals & Clinics: Holds the largest Thalassemia Treatment market share owing to the increase in the number of hospital admissions for the treatment of thalassemia. Moreover, increasing occurrence of thalassemia is also expected to drive this segment.
  • Diagnostic laboratories: This segment holds significant market share owing to the increasing awareness regarding thalassemia treatment.
  • Others: This segment includes research laboratories, educational institutes, among others.
By Region
  • Americas: The largest growing regional market owing to rising awareness about thalassemia and increasing government efforts to support gene therapy. However, Beta-thalassemia disorder is relatively rare in the US.
  • Europe: The introduction of gene therapy for the treatment of thalassemia is expected to boost the growth of market. For instance, in September 2019, Bluebird Bio, Inc. (US) has obtained approval for gene therapy that would remove the need for blood transfusions for people with blood disorder beta-thalassemia.
  • Asia-Pacific: The fastest-growing regional market in thalassemia treatment. Increasing investment in healthcare infrastructure is expected to drive the growth of the market in this region.
  • Middle East & Africa: Increasing adoption rate of blood transfusion treatment in countries such as Turkey and GCC would drive the demand for thalassemia treatment in this region.
Key Players
  • Novartis AG (Switzerland)
  • Bluebird Bio, Inc. (US)
  • Kiadis Pharma (Netherlands)
  • CELGENE CORPORATION (US)
  • Sangamo Therapeutics (US)
  • Acceleron Pharma, Inc. (US)
  • Gamida Cell (Israel)
Posted by at No comments:

Tuesday, 7 July 2020

Top Trends In Amblyopia Market 2020 – 2023 By Growth Factors And Industry Players Overview

Amblyopia is an eye disorder which leads to decreased vision in one or both the eyes due to suppressed input from the brain. The most common cause of amblyopia is a refractive error in one or both eyes, or it might even occur due to muscle imbalance. The other cause of amblyopia is if the infant is born with a cataract, which causes cloudy images. There are four types of amblyopia, namely, Strabismus Amblyopia, Refractive Amblyopia, Deprivation Amblyopia, and Reverse Amblyopia. The global prevalence rate of Amblyopia is 2 to 3% of the infant population. Amblyopia market is driven by growing incidence of ophthalmological disorders such as cataracts, macular degeneration, glaucoma, and refractive errors. According to reports published by the United Kingdom Statistics Authority, in 2015, around 15,900 people were registered as visually impaired. Moreover, according to the Journal of Ophthalmology, as of 2014 there were around 28 million visually impaired people in the European region. With the increasing prevalence, there is increasing in the advancement of treatment and hence influencing the growth of the Amblyopia market size. 
Amblyopia, commonly known as lazy eye, is a vision impairment disorder, in which one or both the eyes have reduced or no vision. Amblyopia can begin during infancy or early childhood. Amblyopia requires detection and diagnosis early in childhood, which otherwise can lead to blindness during later life. On the basis of type, amblyopia can be divided into, Strabismic amblyopia, Refractive amblyopia, Deprivation amblyopia, and Reverse Amblyopia.
Global amblyopia market is expected to grow at a CAGR of 3.80% during the forecast period 2017-2023.
Key Players                                                                                                         
  • Amblyoptica (Holding) Pty Ltd,
  • Amblyotech, Inc,
  • Good-Lite Co,
  • Vivid Vision, Inc.,
  • Cooper Vision,
  • Johnson & Johnson,
  • Novartis AG.,
  • Carl Zeiss AG,
  • HOYA Corporation,
  • Krafty Eye Patches¸
  • Fresnel Prism and Lens Co.,
  • Hilco Vision,
  • McKesson Corporation
Segmentation                      
The global amblyopia market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis the type, it is segmented into strabismus amblyopia, refractive amblyopia, deprivation amblyopia, reverse amblyopia, and other.
On the basis of the diagnosis, it is segmented into visual acuity tests, photo screening, Bruckner test and others.
On the basis of the treatment, it is segmented into eye patches, atropine drops, glasses, video game and others.
On the basis of the end-user, it is segmented into hospitals & pharmacies, ophthalmic clinics, and others.
Regional analysis
The global amblyopia market, on the basis of region, is divided into the Americas, Europe, Asia Pacific and the Middle East & Africa. The Americas accounted for the largest amblyopia market share of 37.9% in 2016 for global amblyopia market. This large share is majorly attributed due to the increasing prevalence of ophthalmological disorders, the presence of major manufacturers, increasing technological advancement and high healthcare expenditure. Europe accounts for the second largest market share, whereas Asia Pacific is expected to grow at the fastest rate with 4.35% CAGR for the forecast period. With lots of opportunity and continuously growing economies, the presence of huge patient population, rapid development in technology and presence of a huge opportunity for the development the region is expected to be the fastest growing region. The Middle East & Africa is growing at a slow pace, and the low income accounted for the least market share in 2016 but is expected to grow in the coming future.
Posted by at No comments:

Blood Testing Market 2020 Covers Global Industry Share, Size, Gross Margin, Future Trends, Demand, Business Insight By Leading Key Players Forecast Till 2023

Market Scenario 
Blood Testing is a laboratory analysis technique that is performed based on the blood sample taken from patient's body through a finger prick or syringes to determine the state of the health. The abnormal functioning of organs can be determined by Blood Testing. These tests are affordable and are commonly performed in hospitals and clinics as a primary checkup for identifying any mild to serious ailments which influence the growth of the Blood Testing market.
The Global market for Blood Testing is expected to grow at a CAGR of approximately 5.5% during 2017 to 2023.
Competitive Analysis
The blood testing market appears fragmented and fiercely competitive due to many large and small players churning the competition in the market.  Through the strategic partnership, acquisition, expansion, product & technology launch, and collaboration, these players try to gain the competitive edge.
Key Players:
The global blood Testing market growth is led by some of the fervent players including Baxter International (US), Abbott Laboratories Inc. (US), Gen-Probe, Inc. (US), Becton Dickinson & Company (US), Novartis Diagnostics (US), Biomerica, Inc. (US), Cepheid Corporation (US), Meridian Bioscience, Inc. (US), Trinity Biotech (US), Siemens Healthcare (Germany), Bio-Rad Laboratories Inc. (US), Grifols (Spain), bioMérieux (France), Nanosphere Inc. (US), Roche Diagnostics (Switzerland), Bruker Corporation (US), Alere Inc. (US), Thermo Fisher Scientific Inc. (US) Cardinal Health (US), Beckman Coulter (US), Danaher Corporation (US), and Trividia Health (US)
Industry, Innovation & Related News
September 07, 2018 – Scientists in Australia published their study of a novel blood test they have developed in the JCI Insight Journal. The new blood test that can potentially identify whether a person who had a heart attack in the past is at high risk of having another one. certain lipid biomarkers or fats in the blood to improve upon traditional risk factors in predicting heart disease. The researchers hope to trial it in Australia in the next two to three years.
August 13, 2018 – Engineering for All (Israel), announced the development of a handheld programmable device, named as RevDx (Revolution Diagnostics) that performs automated blood analysis and diagnostics at the point of care. RevDx is meant for anyplace without reliable access to a lab, electricity or Internet connection.
Market Drivers
Growing incidents of chronic diseases and conditions such as cancer, diabetes, heart disease along with the organ failure cases drive the demand for blood testing in multiplications. Needless to say, that the blood testing market is ever increasing. Also, great technological strides being made in electronic monitoring devices and substantial investments transpired into R&D activities are in turn, paying off well, expanding the market size.

Additional factors supporting the market growth include the ever-increasing population that is getting inclined towards the sedentary lifestyle and urbanization. Improving economic conditions are rapidly availing access to the excellent health care, increasing the healthcare expenditures and eventually the market growth.

Conversely, lack of awareness towards the availability and advantages of blood testing is obstructing the market growth.  Also, the unmet clinical needs coupled with the unavailability of external funding; especially in the developing regions are obstructing the market growth. Nevertheless, increasing demand for personal & hand-held diagnostic devices & augmenting demand for the blood testing in the diagnostics that can give fastest & accurate results is fostering the market growth.

Segmentation
The global Blood Testing market has been segmented on the basis of test type, disease, method, and end-user.
On the basis of test type, the global Blood Testing market can be segmented into glucose testing, lipid panel testing, direct LDL testing, Prostate Specific Antigen (PSA) testing, Blood Urea Nitrogen (BUN) testing, A1C testing, high sensitivity C-Reactive Protein (hs-CRP) testing, Vitamin D testing, alt testing, thyroid stimulating hormone testing, creatinine testing, serum nicotine/cotinine testing, AST testing, cortisol testing, testosterone testing, and others.
On the basis of disease, the global Blood Testing market can be segmented into anemia, infection, leukemia, hypokalemia, kidney disorders, heart attack, coronary heart disease, and other diseases.
On the basis of method, the global Blood Testing market can be segmented into manual blood culture testing and automated blood culture testing.
The automated blood culture testing segment is classified into automated blood culture system, blood culture instruments, and others      
On the basis of end-user, the global Blood Testing market is segmented into hospitals, clinics, diagnostic centers, research labs, and others.
Regional Analysis                     
The global Blood Testing market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas region accounted for the largest market share of the global Blood Testing market owing to the rising incidence of diseases such as kidney disorders, blood stream infections, other infections, high demand for rapid diagnostic tests, and growing aging population.
The European Blood Testing market is the second largest market owing to the increasing awareness of chronic infection diseases due to the initiatives undertaken by private companies, government organizations, and educational institutions.
The Asia Pacific region is expected to grow rapidly during the forecast period owing to the increasing awareness of the importance of diagnostics in personalized medicines and due to government initiatives, that promote the use of personalized medicines. Furthermore, the increase in a number of government schemes to curb the rising healthcare expenditures in emerging economies is expected to drive the regional market growth.
The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure.
Posted by at No comments:

Chordoma Disease Market Global Analysis, Size, Share, Trends, And Forecast 2020 To 2023

Market Scenario
Chordoma is a rare, slow-growing type of bone cancer. The increasing awareness programs about cancers led by WHO and UNICEF and the rising healthcare investment in the emerging markets are anticipated to exhibit more opportunities for the growth of the chordoma disease market trends.
The global chordoma disease market has been segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, the global chordoma disease market is segmented into biopsy, imaging, blood tests, and others. The imaging segment is further divided into x-ray, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, Positron Emission Tomography (PET) scanning, and bone scan.
On the basis of treatment, the global chordoma disease market is segmented into chemotherapy, radiation therapy, cryosurgery, surgical treatments, radiosurgery, targeted therapy, and others. The surgery segment is further classified into radical resections, sacral chordoma, spinal chordoma, skull base chordoma, and others. The chemotherapy segment is classified into methotrexate, doxorubicin, and others. Furthermore, the targeted therapy segment is divided into bevacizumab, erlotinib, and others.
On the basis of end-user, the global chordoma disease market is segmented into hospitals, clinics, cancer care centers, and others.
Regionally, the Americas chordoma disease market is segmented into two major regions, namely, North America and South America.
The Americas region holds the largest share of the global chordoma disease market owing to the increasing demand for targeted therapies and growing health concerns. As per an estimate by the American Cancer Society, about 3,300 new cases of bone cancer were diagnosed in 2016 with a death toll of about1490. Thus, the high prevalence of chondroid chordomas is the major hurdle in the market growth. 
Key Players
Some of the key players in the global chordoma disease market are AstraZeneca plc (U.K.), Amgen, Inc. (U.S.), Actavis plc (U.S.), Bristol-Myers Squibb and Company (U.S.), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline plc (UK), Novartis International AG (Switzerland), Pfizer, Inc. (U.S.), Sanofi S.A. (France), Debiopharm Group (Switzerland), Bayer AG (Germany), Johnson & Johnson (U.S.), Merck & Co., Inc. (U.S.), Optivus Proton Therapy, Inc. (U.S.), ProCure Treatment Centers, Inc. (U.S.), Varian Medical Systems, Inc.(U.S.), Amura Holdings Ltd. (U.S.), Catena pharmaceuticals Inc. (U.S.), Celldex therapeutics Inc. (U.S.), Eckert & Ziegler BEBIG (Germany), Infinity Pharmaceuticals (U.S.), Medivir AB (Sweden), Merrion Pharmaceuticals Plc. (U.S.), and others.
Regional Analysis                    
The global chordoma disease market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas region accounted for the largest market share of the global chordoma disease market owing to the high prevalence of bone cancer in the region and aging population, along with high favorable reimbursement policies in the region. As per the American Cancer Society in 2017, about 3,260 people are projected to be diagnosed with primary bone cancer in the U.S. (1,820 men and boys and 1,440 women and girls).
The European chordoma disease market is anticipated to emerge as the second largest market owing to the development of the pharmaceutical and medical industries. According to the Cancer Research U.K. organization in 2014, about 580 new cases of bone sarcoma were found in the U.K.
The Asia Pacific region is expected to grow rapidly during the forecast period owing to less awareness regarding bone cancer among the population and less availability of effective treatment option for bone cancer in the region. For instance, in September 2016, Dr. Reddy's Laboratories entered into a strategic collaboration with Amgen for marketing and distributing Prolia (denosumab), Vectibix (panitumumab), and Xgeva (denosumab) in India.
The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure.
Posted by at No comments:
Subscribe to: Posts (Atom)